Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan is an effective, non-peptide, and orally active interleukin-1β convertingenzyme inhibitor (Ki: 1.4 nM). Pralnacasan has the potential for osteoarthritis and rheumatoid a